Latest Treatments for Cardiorenal Metabolic Disease
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".
Deadline for manuscript submissions: 25 September 2024 | Viewed by 51
Special Issue Editor
2. Department of Cardiology, University of Warwick Medical School & Coventry University, Coventry CV4, UK
Interests: heart failure with preserved ejection fraction (HFpEF); cardiorenal syndrome; cardiac amyloidosis; palliative care in heart failure; vascular aspects of HFpEF; exercise rehabilitation in pulmonary hypertension; myocardial fatigue; electrical muscle stimulation
Special Issue Information
Dear Colleagues,
The fact that the heart and the kidneys are interdependent was recognised close to 200 years ago, but the definition and classification of cardiorenal syndrome are fairly recent developments. The classification takes account of acute or chronic dysfunction in one of these two organs, producing acute or chronic dysfunction in the other. The presence of this dual-organ dysfunction is associated with increased morbidity, mortality and hospitalisation. Despite recent strides made in further understanding the pathophysiology of cardiorenal syndrome and the development of diagnostic biomarkers and imaging techniques, its management remains challenging and in development. Some earlier guidelines encouraged the creation of cardiorenal teams to focus on outpatient and inpatient care for these patients. However, with the arrival of new drugs such as SGLT2 inhibitors, which have a beneficial effect not only on the glycaemic control of type 2 diabetic patients but also on renal and cardiac dysfunction, the current focus is on developing multidisciplinary cardiorenal–metabolic multidisciplinary teams. This seems to be a sensible strategy given that diabetes is a major cause of both cardiac and renal disease and is closely interlinked with both. Cardiorenal metabolic disease also includes hypertension and hyperlipidaemia. But how should we treat all the three systems simultaneously?
I welcome you submissions within this fascinating new area to assist in the formation of this Special Issue of JCM entitled “Latest Treatments for Cardiorenal Metabolic Disease”.
Prof. Dr. Prithwish Banerjee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiorenal syndrome
- treatment
- multidisciplinary teams
- classification
- cardiorenal metabolic disease
